HKD 13.91: Ping An Healthcare 1833.HK HKSE ahead of 24 Feb earnings: analyst range

1833.HK stock trades at HKD 13.91 intraday in Hong Kong on 19 Feb 2026, with volume at 1,375,492 ahead of an earnings release scheduled for 24 Feb 2026. Investors will watch revenue and margin details after a year-high of HKD 24.40 and a year-low of HKD 6.06. Key metrics show EPS HKD 0.10 and a trailing PE of 139.10, which connects valuation to near-term earnings risk. This earnings spotlight reviews the numbers, analyst context, and what the Meyka AI forecast implies for intraday trading and the coming report.

Earnings preview: 1833.HK stock earnings and calendar

Ping An Healthcare and Technology (1833.HK) reports after market hours on 24 Feb 2026. Analysts expect the company to detail online consultation volumes, consumer healthcare sales, and hospital referral margins. The stock opened at HKD 13.85 today and is trading near its 200-day average of HKD 13.69, making the print a potential catalyst for a volatility leg.

Valuation snapshot: 1833.HK stock financials and ratios

At HKD 13.91, market cap stands at HKD 29.58B with 2,126,594,845 shares outstanding. Trailing PE reads 139.10 and price-to-book is 2.52, while price-to-sales is 5.01. Cash per share is HKD 1.75 and book value per share is HKD 4.88. These metrics show premium valuation versus the healthcare sector average PE of 27.74, signalling higher growth expectations priced in.

Meyka Stock Grade: 1833.HK stock rating and model

Meyka AI rates 1833.HK with a score out of 100: 70.32 | Grade: B+ | Suggestion: BUY. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects a yearly target of HKD 21.99, implying an upside of 58.15% from the current HKD 13.91. Forecasts are model-based projections and not guarantees. We note the score reflects recovery vs a volatile history and is not investment advice.

Technical picture: 1833.HK stock intraday technicals

Intraday indicators show a short-term neutral to slightly bearish tone: RSI 37.14, MACD histogram at -0.08, ATR HKD 0.56, and Bollinger lower band at HKD 13.09. Volume today is 1,375,492, well below the 30-day average of 14,783,771, which may limit strong directional moves until the earnings release.

Catalysts and risks: 1833.HK stock opportunities and threats

Primary catalysts include above-consensus revenue, improved gross margin from consumer healthcare, and positive guidance on active users. Risks are slower-than-expected monetisation, a miss on margin recovery, or broad sector weakness. Regulatory or reimbursement changes in China could also compress multiples quickly given the current premium valuation.

Trading implications: 1833.HK stock intraday strategy

For intraday and short-term traders, watch price action around HKD 13.61–13.92 (today’s range) and the 200-day average HKD 13.69. Options or pairs trades (if available) could hedge earnings exposure. Longer-term investors should weigh the premium PE against Meyka AI’s growth forecasts and the company’s cash cushion of HKD 1.75 per share.

Final Thoughts

Key takeaways for 1833.HK stock ahead of earnings on 24 Feb 2026: the share price at HKD 13.91 prices in meaningful growth, shown by a high trailing PE of 139.10 and price-to-sales of 5.01. Meyka AI’s forecast model projects a yearly target of HKD 21.99, an implied upside of 58.15%, while a nearer-term quarterly forecast sits at HKD 18.56. The company’s balance sheet is strong with current ratio 3.15 and cash per share HKD 1.75, but execution on monetisation and margin recovery must match expectations. Intraday traders should note low relative volume today and technicals pointing to limited momentum. We highlight sector context: healthcare peers trade a lower average PE of 27.74, so any positive surprise could re-rate the stock, while misses could accelerate a multiple contraction. Use the upcoming report to reassess risk/reward and price targets; forecasts are model-based projections and not guarantees. Meyka AI provides this as AI-powered market analysis to guide further research.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.